Clinical trials: High Risk Cancer
Colorectal Cancer, Regorafenib
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy
- Conditions
- Colorectal Cancer, Regorafenib, High Risk Patients
- Trial name
- NCT07071961
- Testing
- Regorafenib (CT), Lorigerlimab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
It is hypothesized that significantly more patients would prefer oral decitabine/cedazuridine to subcutaneous (SC) azacitidine (AZA) due to several factors, including improved treatment convenience, the reduced risk of nosocomial…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference
- Trial name
- PREFER-HMA (NCT05883956)
- Testing
- Subcutaneous azacitidine, Oral decitabine/cedazuridine
- Where
- 11 sites in Australia, New Zealand
- Volunteers
- 13 people
- Sponsor
- Otsuka Australia Pharmaceutical Pty Ltd
Hematologic Malignancies
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with…
- Trial name
- NCT04588922
- Testing
- SLS009, venetoclax, azacitidine
- Where
- 32 sites in United States, China
- Volunteers
- 160 people
- Sponsor
- Sellas Life Sciences Group
Pancreatic Neoplasms, Pancreatic Cancer
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
This is a phase II study. It is designed to provide information about if high-dose ascorbate (vitamin C) increases survival for pancreatic cancer patients.
- Trial name
- PACMAN-II (NCT01515046)
- Testing
- Gemcitabine with escalating ascorbic acid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Joseph J. Cullen
Neuroblastoma
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and…
- Trial name
- NCT03363373
- Testing
- GM-CSF + Naxitamab
- Where
- 20 sites in United States, Canada and 7 more
- Volunteers
- 122 people
- Sponsor
- Y-mAbs Therapeutics
High Risk Neuroblastoma, Recurrent Neuroblastoma
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
This phase I trial is to find out the best dose, possible benefits and/or side effects of magrolimab in combination with dinutuximab in treating patients with neuroblastoma that has come back (relapsed) or does not respond to…
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma
- Trial name
- NCT04751383
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 11 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Fatigue, Cognitive Impairment
Cognitive Function After Stem Cell Transplantation
The trial will evaluate the effects of an exercise program on the physical and cognitive performance of patients with hematological neoplastic diseases after high dose chemotherapy with stem cell support.
- Conditions
- Fatigue, Cognitive Impairment, Stem Cell Transplantation
- Trial name
- NCT00884338
- Testing
- Endurance exercise, Counseling
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Charite University, Berlin, Germany
Breast Cancer
Community Hospital Identification of High CV Risk Patients During Cancer Treatment
The overall of this proposal is to test in community hospitals the utility of a 10-min magnetic resonance imaging (MRI) scan protocol combined with proprietary image analysis algorithms for detecting early cardiovascular (CV)…
- Trial name
- CHI (NCT02566109)
- Testing
- Fast MRI
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Pancreatic Cancer, Pancreatic Cancer
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with…
- Conditions
- Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable
- Trial name
- NCT03908333
- Testing
- Ascorbic Acid, Paclitaxel protein-bound, Cisplatin
- Where
- 6 sites in United States
- Sponsor
- Medical College of Wisconsin
Acute Myelogenous Leukemia, Myeloid Leukemia in Remission
Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia
The purpose of this study is to evaluate the safety and the efficacy of combined treatment strategy of WT1ASCI, infusion of ex vivo regulatory T cells depleted T lymphocytes and in vivo regulatory T cells depletion as…
- Conditions
- Acute Myelogenous Leukemia, Myeloid Leukemia in Remission, Effects of Immunotherapy
- Trial name
- ASCI (NCT01513109)
- Testing
- Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Jules Bordet Institute
Bladder Cancer
A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
This is a Phase 1, multicenter, open-label study of intravesical Toca 511 followed by oral Toca FC in patients with high grade (HG) non-muscle invasive bladder cancer (NMIBC), with cohort expansion at the recommended Phase 2…
- Trial name
- NCT04089163
- Testing
- Toca 511, Toca FC (extended-release formulation of flucytosine)
- Sponsor
- Tocagen Inc.
Nausea, Vomiting
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
The purpose of this study is to help answer the following research question: Whether administration of an aprepitant containing regimen, an olanzapine containing regimen or regimen containing both will prevent nausea and vomiting…
- Trial name
- NCT02939287
- Testing
- o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1, Olanzapine10 mg orally daily on Days -1,0,+1 and +2, Aprepitant plus Olanzapine
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Rush University Medical Center
Cervical Cancer, Locally Advanced Cervical Cancer
Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy
Multicenter, Observational, Retrospective charts review. Observational study with descriptive purpose only. Retrospective data capture in consecutive patients diagnosed with CC who attended the Oncologic Clinics from Jan 2018 to…
- Conditions
- Cervical Cancer, Locally Advanced Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer
- Trial name
- RETRACE (NCT06771193)
- Where
- 11 sites in Italy
- Volunteers
- 200 people
- Sponsor
- MSD Italia S.r.l.
High Risk Population of Gastric Cancer
Application of OE in Diagnosis of EGC
The main purpose of this study is to evaluate application value of OE mode 2 in the diagnosis of early gastric cancer The Secondary purpose is to evaluate application value of OE mode 1 in differentiating the diagnosis of…
- Trial name
- NCT04720521
- Testing
- OE+white light
- Where
- China
- Volunteers
- 2,454 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
High-grade Extra Pulmonary Neuroendocrine Cancer
TAS-102 in Extrapulmonary Neuroendocrine Carcinoma
The purpose of this study is to test the safety and efficacy of drug, TAS-102 (trifluridine/tipiracil), in patients with extrapulmonary (outside the lung) high-grade neuroendocrine cancer.
- Trial name
- TAS-102 NEC (NCT04042714)
- Testing
- All patients- TAS-102
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Baylor Research Institute
General Surgery, Cancer of Colon
Preoperative High Protein vs Immunodiet in Surgical Cancer Patients
Immunomodulating nutrition is supposed to reduce the number of complications and the legnth of the hospital stay during the postoperative period in patients after major gastrointestinal surgery.
- Trial name
- Preop immuno (NCT03980704)
- Testing
- IMPACT, resource protein
- Where
- Poland
- Volunteers
- 299 people
- Sponsor
- Stanley Dudrick's Memorial Hospital
Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent).
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma
- Trial name
- NCT05950464
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection
- Where
- 14 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Rhabdomyosarcoma
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
This phase III trial compares higher dose chemotherapy, with vincristine, dactinomycin and cyclophosphamide, over a shorter amount of time to lower dose chemotherapy plus maintenance, with vincristine, dactinomycin…
- Trial name
- NCT07466316
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 87 sites in United States, Canada
- Volunteers
- 342 people
- Sponsor
- Children's Oncology Group
Recurrent Rectal Cancer
Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer
This pilot study hypothesizes that hyperthermia delivered via magnetic resonance-guided focused ultrasound (MRg-FU) is technically feasible and can be safely used in combination with concurrent reirradiation and chemotherapy for…
- Trial name
- NCT02528175
- Testing
- Magnetic resonance-guided focused ultrasound, Standard Radiation, Chemotherapy
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- William Chu, MD, MSc, FRCPC
Ewing Sarcoma, Ewing Sarcoma of Bone
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD
This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.
- Conditions
- Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT06068075
- Testing
- FoundationOne Liquid CDx
- Where
- 15 sites in United States
- Volunteers
- 340 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.